Zhengye Biotechnology (ZYBT) Competitors $5.55 0.00 (0.00%) As of 07/25/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock ZYBT vs. ELVN, AVDL, ARDX, DYN, GPCR, BGM, GHRS, AKBA, SANA, and AMPHShould you be buying Zhengye Biotechnology stock or one of its competitors? The main competitors of Zhengye Biotechnology include Enliven Therapeutics (ELVN), Avadel Pharmaceuticals (AVDL), Ardelyx (ARDX), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), BGM Group (BGM), GH Research (GHRS), Akebia Therapeutics (AKBA), Sana Biotechnology (SANA), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical products" industry. Zhengye Biotechnology vs. Its Competitors Enliven Therapeutics Avadel Pharmaceuticals Ardelyx Dyne Therapeutics Structure Therapeutics BGM Group GH Research Akebia Therapeutics Sana Biotechnology Amphastar Pharmaceuticals Zhengye Biotechnology (NASDAQ:ZYBT) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk. Is ZYBT or ELVN more profitable? Zhengye Biotechnology's return on equity of 0.00% beat Enliven Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zhengye BiotechnologyN/A N/A N/A Enliven Therapeutics N/A -31.84%-30.09% Do analysts recommend ZYBT or ELVN? Enliven Therapeutics has a consensus price target of $41.20, indicating a potential upside of 94.34%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Enliven Therapeutics is more favorable than Zhengye Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Enliven Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings and valuation, ZYBT or ELVN? Zhengye Biotechnology has higher revenue and earnings than Enliven Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZhengye Biotechnology$25.53M10.25$1.55MN/AN/AEnliven TherapeuticsN/AN/A-$89.02M-$1.92-11.04 Does the media refer more to ZYBT or ELVN? In the previous week, Enliven Therapeutics had 7 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 8 mentions for Enliven Therapeutics and 1 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 1.87 beat Enliven Therapeutics' score of 0.51 indicating that Zhengye Biotechnology is being referred to more favorably in the media. Company Overall Sentiment Zhengye Biotechnology Very Positive Enliven Therapeutics Positive Do insiders and institutionals believe in ZYBT or ELVN? 95.1% of Enliven Therapeutics shares are held by institutional investors. 25.9% of Enliven Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryEnliven Therapeutics beats Zhengye Biotechnology on 6 of the 11 factors compared between the two stocks. Get Zhengye Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZYBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYBT vs. The Competition Export to ExcelMetricZhengye BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$261.77M$3.05B$5.70B$9.50BDividend YieldN/A2.37%4.58%4.00%P/E RatioN/A21.3228.3920.08Price / Sales10.25280.80430.0899.95Price / Cash53.8642.7636.2258.56Price / Book5.448.378.675.88Net Income$1.55M-$55.19M$3.25B$258.89M7 Day Performance-2.46%5.86%4.30%3.70%1 Month Performance-21.28%17.29%10.57%11.71%1 Year PerformanceN/A4.39%35.68%17.98% Zhengye Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYBTZhengye BiotechnologyN/A$5.55flatN/AN/A$261.77M$25.53M0.00278Positive NewsGap UpELVNEnliven Therapeutics2.6179 of 5 stars$21.56-1.4%$41.20+91.1%-15.3%$1.07BN/A-11.2350Insider TradeGap UpAVDLAvadel Pharmaceuticals2.0935 of 5 stars$11.23+2.3%$18.33+63.3%-32.3%$1.06B$169.12M-41.5970ARDXArdelyx4.1115 of 5 stars$4.43+0.2%$10.89+145.8%-21.9%$1.06B$333.61M-20.1490DYNDyne Therapeutics3.8174 of 5 stars$9.21+0.4%$40.63+341.1%-76.7%$1.04BN/A-2.57100GPCRStructure Therapeutics2.9261 of 5 stars$18.19+0.3%$76.17+318.7%-53.2%$1.04BN/A-20.91136Positive NewsBGMBGM GroupN/A$10.04-5.6%N/AN/A$1.03B$25.10M0.00298High Trading VolumeGHRSGH Research2.1102 of 5 stars$16.69-14.4%$32.00+91.7%+22.8%$1.01BN/A-21.1310AKBAAkebia Therapeutics3.7957 of 5 stars$3.85+0.3%$6.75+75.3%+140.5%$1.01B$160.18M-18.33430Positive NewsSANASana Biotechnology3.1717 of 5 stars$4.87+9.7%$9.17+88.2%-18.2%$1.00BN/A-5.53380AMPHAmphastar Pharmaceuticals4.4131 of 5 stars$21.35+0.8%$32.33+51.4%-46.9%$998.88M$731.97M7.742,028 Related Companies and Tools Related Companies ELVN Alternatives AVDL Alternatives ARDX Alternatives DYN Alternatives GPCR Alternatives BGM Alternatives GHRS Alternatives AKBA Alternatives SANA Alternatives AMPH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZYBT) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredIt’s my duty to share the “truth” I see behind this bible verseFormer CIA advisor Jim Rickards believes President Trump has just unlocked what the Bible foretold — a $150 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zhengye Biotechnology Holding Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zhengye Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
